Literature DB >> 11991763

Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus.

Qi-Sheng Chen1, Wei-Zheng Wei, Takeshi Shimahara, Cui-Wei Xie.   

Abstract

The perforant path projecting from the entorhinal cortex to the hippocampal dentate gyrus is a particularly vulnerable target to the early deposition of amyloid beta (Abeta) peptides in Alzheimer's brain. The authors previously showed that brief applications of Abeta at subneurotoxic concentrations suppressed the early-phase long-term potentiation (E-LTP) in rat dentate gyrus. The current study further examines the effect of Abeta on the late-phase LTP (L-LTP) in this area. Using multiple high-frequency stimulus trains, a stable L-LTP lasting for at least 3 h was induced in the medial perforant path of rat hippocampal slices. Bath application of Abeta(1-42) (0.2-1.0 microM) during the induction trains attenuated both the initial and late stages of L-LTP. On the other hand, Abeta(1-42) perfusion within the first hour following the induction primarily impaired the late stage of L-LTP, which resembled the action of the protein synthesis inhibitor emetine. Blockade of calcineurin activity with FK506 or cyclosporin A completely prevented Abeta-induced L-LTP deficits. These results suggest that Abeta(1-42) impaired both the induction and maintenance phase of dentate L-LTP through calcineurin-dependent mechanisms. In the concentration range effective for inhibiting L-LTP, Abeta(1-42) also reduced the amplitude of NMDA receptor-mediated synaptic currents in dentate granule cells via a postsynaptic mechanism. In addition, concurrent applications of Abeta(1-42) with the protein synthesis inhibitor caused no additive reduction of L-LTP, indicating a common mechanism underlying the action of both. Thus, inhibition of NMDA receptor channels and disruption of protein synthesis were two possible mechanisms contributing to Abeta-induced L-LTP impairment. Copyright 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991763     DOI: 10.1006/nlme.2001.4034

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  68 in total

Review 1.  How long will long-term potentiation last?

Authors:  Wickliffe C Abraham
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-04-29       Impact factor: 6.237

Review 2.  Synaptic plasticity in animal models of early Alzheimer's disease.

Authors:  Michael J Rowan; Igor Klyubin; William K Cullen; Roger Anwyl
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-04-29       Impact factor: 6.237

Review 3.  Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

Review 4.  New developments on the role of NMDA receptors in Alzheimer's disease.

Authors:  Roberto Malinow
Journal:  Curr Opin Neurobiol       Date:  2011-09-29       Impact factor: 6.627

5.  Donepezil in a narrow concentration range augments control and impaired by beta-amyloid peptide hippocampal LTP in NMDAR-independent manner.

Authors:  Nadezhda A Kapai; Julia V Bukanova; Elena I Solntseva; Vladimir G Skrebitsky
Journal:  Cell Mol Neurobiol       Date:  2011-10-04       Impact factor: 5.046

6.  Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex.

Authors:  Nicola Origlia; Camilla Bonadonna; Alfredo Rosellini; Elena Leznik; Ottavio Arancio; Shirley Shidu Yan; Luciano Domenici
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

Review 7.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

8.  PTEN recruitment controls synaptic and cognitive function in Alzheimer's models.

Authors:  Shira Knafo; Cristina Sánchez-Puelles; Ernest Palomer; Igotz Delgado; Jonathan E Draffin; Janire Mingo; Tina Wahle; Kanwardeep Kaleka; Liping Mou; Inmaculada Pereda-Perez; Edvin Klosi; Erik B Faber; Heidi M Chapman; Laura Lozano-Montes; Ana Ortega-Molina; Lara Ordóñez-Gutiérrez; Francisco Wandosell; Jose Viña; Carlos G Dotti; Randy A Hall; Rafael Pulido; Nashaat Z Gerges; Andrew M Chan; Mark R Spaller; Manuel Serrano; César Venero; José A Esteban
Journal:  Nat Neurosci       Date:  2016-01-18       Impact factor: 24.884

9.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease.

Authors:  J Steven Jacobsen; Chi-Cheng Wu; Jeffrey M Redwine; Thomas A Comery; Robert Arias; Mark Bowlby; Robert Martone; John H Morrison; Menelas N Pangalos; Peter H Reinhart; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

Review 10.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.